Compare Immunovant Inc. Common Stock (IMVT) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.41 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 21.2× Immunovant Inc. Common Stock's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| IMVT | VIG | |
|---|---|---|
Market Cap | $6.25B | $132.40B |
Volume | 1,755,411 | 1,287,188 |
Sector | Health | — |
52-Week High | $44.96 | $246.61 |
52-Week Low | $17.03 | $210.70 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $236.99, down 0.32% on the day, with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5%, though year-to-date growth remains modest at 3.3%.
Outlook remains positive for long-term investors seeking dividend growth, with VIG averaging 10% annual returns since inception. Key risks include slower dividend growth pace and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may lag during strong growth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
